Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?

被引：0
|
作者：
Landi, Lorenza [1 ]
Cappuzzo, Federico [1 ]
机构：
[1] Osped Civile Livorno, Ist Toscano Tumori, I-57100 Livorno, Italy
来源：
JOURNAL OF THORACIC DISEASE | 2012年 / 4卷 / 02期
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER; ERLOTINIB; GEFITINIB;
D O I：
10.3978/j.issn.2072-1739.2012.03.04
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：226 / 228
页数：3
相关论文
共 50 条
  • [31] TREATMENT PATTERNS AMONG FRONT-LINE GLIOBLASTOMA PATIENTS IN FIVE EUROPEAN COUNTRIES
    Jiang, S.
    Hill, K.
    Patel, D.
    Worthington, K.
    VALUE IN HEALTH, 2015, 18 (07) : A492 - A493
  • [32] Cost-Effectiveness of 1st-Line Treatment EGFR-TKIs for Advanced NSCLC Patients Harboring EGFR Mutation in Mexico
    Ramirez Tirado, L. A.
    Guzman, S.
    Goycochea-Robles, C.
    Barron, F.
    Cabrera-Miranda, L.
    Flores-Estrada, D.
    Arrieta, O. G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S846 - S846
  • [33] Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations
    Imai, Hisao
    Minemura, Hiroyuki
    Sugiyama, Tomohide
    Yamada, Yutaka
    Kaira, Kyoichi
    Kanazawa, Kenya
    Kasai, Takashi
    Kaburagi, Takayuki
    Minato, Koichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 119 - 127
  • [34] Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
    Masuda, T.
    Imai, H.
    Kuwako, T.
    Miura, Y.
    Yoshino, R.
    Kaira, K.
    Shimizu, K.
    Sunaga, N.
    Tomizawa, Y.
    Ishihara, S.
    Mogi, A.
    Hisada, T.
    Minato, K.
    Takise, A.
    Saito, R.
    Yamada, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (09): : 702 - 709
  • [35] Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
    T. Masuda
    H. Imai
    T. Kuwako
    Y. Miura
    R. Yoshino
    K. Kaira
    K. Shimizu
    N. Sunaga
    Y. Tomizawa
    S. Ishihara
    A. Mogi
    T. Hisada
    K. Minato
    A. Takise
    R. Saito
    M. Yamada
    Clinical and Translational Oncology, 2015, 17 : 702 - 709
  • [36] A multicenter phase II study to evaluate efficacy and safety of gefitinib as the first-line treatment for Korean patients (pts) with advanced pulmonary adenocarcinoma harboring EGFR mutations
    Kim, D.
    Lee, S.
    Lee, J.
    Lee, M.
    Kang, J.
    Kim, S.
    Shin, S.
    Kim, H.
    Heo, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs
    Tao, D.
    Lei, H.
    Tan, J.
    Yang, D.
    Jiang, Y.
    Zhou, W.
    Wang, Y.
    Wu, Y.
    ANNALS OF ONCOLOGY, 2023, 34
  • [38] Afatinib vs. Osimertinib as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Hoang, T. T. A.
    Nguyen, T. T. T.
    Pham, C. T. M.
    Dong, H. Q.
    Nguyen, K. T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S626 - S627
  • [39] Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations
    Zheng, Linpeng
    Wang, Yanmei
    Xu, Zihan
    Yang, Qiao
    Zhu, Guangkuo
    Liao, Xing-Yun
    Chen, Xiewan
    Zhu, Bo
    Duan, Yuzhong
    Sun, Jianguo
    ONCOLOGIST, 2019, 24 (08): : 1031 - +
  • [40] The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation
    Sgambato, A.
    Casaluce, F.
    Maione, P.
    Rossi, A.
    Rossi, E.
    Napolitano, A.
    Palazzolo, G.
    Bareschino, M. A.
    Schettino, C.
    Sacco, P. C.
    Ciadiello, F.
    Gridelli, C.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (20) : 3337 - 3352
12345